{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:49:35Z","timestamp":1793191775791,"version":"4.5.0"},"reference-count":31,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Denecimig (Mim8) is a next-generation, activated factor VIII mimetic, fully human bispecific immunoglobulin G4 antibody in development for subcutaneous prophylaxis in bleeding episodes, for patients with hemophilia A (HA) with\/without inhibitors. FRONTIER4 is an open-label extension study to assess the safety and efficacy of denecimig. Here we present an interim analysis of patients receiving denecimig once every 2 weeks (Q2W) in FRONTIER4. Patients with HA aged \u226512 years who had participated in the denecimig phase 2 study and \u226512 weeks of its extension and entered arm 1 of the FRONTIER4 phase 3 study received denecimig Q2W for 26 weeks using a tiered dosing approach according to body weight range. The primary end point was the number of treatment-emergent adverse events (TEAEs); secondary end points included injection site reactions, occurrence of anti-denecimig antibodies, denecimig plasma concentrations, and number of treated bleeds. Thirty-seven patients were enrolled who received denecimig for a mean of 1.73 years in the phase 2 study. Sixty TEAEs were reported in 20 patients. Most TEAEs were mild\/moderate in severity (98.3%), unlikely to be related to denecimig (75.0%), and resolved during the time frame of this analysis (90.0%). No TEAEs led to permanent discontinuation of denecimig, and none were fatal. Two patients reported 14 injection site reactions. Denecimig plasma concentrations were stable through week 26. The estimated mean annualized bleeding rate was 0.38 bleeds per patient year. Most patients experienced zero treated bleeds (83.8%). In summary, denecimig administered Q2W was well tolerated, with few patients experiencing treated bleeds and no safety concerns. This trial was registered at www.clinicaltrials.gov as NCT05685238.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019095","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T02:04:12Z","timestamp":1784340252000},"page":"6946-6953","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Denecimig (Mim8) prophylaxis once every 2 weeks for hemophilia A with or without inhibitors: 26-week results from FRONTIER4"],"prefix":"10.1182","volume":"10","author":[{"given":"Tadashi","family":"Matsushita","sequence":"first","affiliation":[{"name":"1Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atanas","family":"Banchev","sequence":"additional","affiliation":[{"name":"2Department of Paediatric Haematology and Oncology, University Hospital \u201cTzaritza Giovanna - ISUL,\u201d Medical University Sofia, Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Bovet","sequence":"additional","affiliation":[{"name":"3Novo Nordisk Health Care AG, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratima","family":"Chowdary","sequence":"additional","affiliation":[{"name":"4Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llenalia Mar\u00eda","family":"Garc\u00eda Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"5Novo Nordisk Health Care AG, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Jim\u00e9nez-Yuste","sequence":"additional","affiliation":[{"name":"6Hematology Department, La Paz University Hospital-IdiPaz, Universidad Aut\u00f3noma Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaan","family":"Kavakli","sequence":"additional","affiliation":[{"name":"7Division of Hemato-Oncology, Department of Pediatrics, Ege University School of Medicine, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1300-7135","authenticated-orcid":false,"given":"Johanna A.","family":"Kremer Hovinga","sequence":"additional","affiliation":[{"name":"8Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7877-4784","authenticated-orcid":false,"given":"Jerzy","family":"Windyga","sequence":"additional","affiliation":[{"name":"9Department of Hemostasis Disorders and Internal Medicine, Laboratory of Hemostasis and Metabolic Diseases, Institute of Hematology and Transfusion Medicine, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6013-1254","authenticated-orcid":false,"given":"Guy","family":"Young","sequence":"additional","affiliation":[{"name":"10Cancer and Blood Disease Institute, Children\u2019s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"suppl 6","key":"2026102711113996600_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"9","key":"2026102711113996600_bib2","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"2026102711113996600_bib3","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"2026102711113996600_bib4","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"2026102711113996600_bib5","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/bloodadvances.2019001311","article-title":"Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study","volume":"4","author":"Warren","year":"2020","journal-title":"Blood Adv"},{"issue":"17","key":"2026102711113996600_bib6","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood-2016-02-683169","article-title":"Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project","volume":"129","author":"Manco-Johnson","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2026102711113996600_bib7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/hematolrep15010014","article-title":"Haemophilia A: a review of clinical manifestations, treatment, mutations, and the development of inhibitors","volume":"15","author":"Sarmiento Doncel","year":"2023","journal-title":"Hematol Rep"},{"issue":"3","key":"2026102711113996600_bib8","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/hae.13754","article-title":"From the voices of people with haemophilia A and their caregivers: challenges with current treatment, their impact on quality of life and desired improvements in future therapies","volume":"25","author":"Wiley","year":"2019","journal-title":"Haemophilia"},{"issue":"2","key":"2026102711113996600_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000121828","article-title":"Assessment of treatment practice patterns for severe hemophilia A: a global nurse perspective","volume":"119","author":"Khair","year":"2008","journal-title":"Acta Haematol"},{"issue":"11","key":"2026102711113996600_bib10","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1182\/bloodadvances.2023012285","article-title":"Predictive parameters for spontaneous joint bleeding during emicizumab prophylaxis","volume":"8","author":"Arcudi","year":"2024","journal-title":"Blood Adv"},{"issue":"14","key":"2026102711113996600_bib11","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood.2020010331","article-title":"A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice","volume":"138","author":"\u00d8stergaard","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2026102711113996600_bib12","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/jth.15682","article-title":"A novel next-generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: results from safety studies in cynomolgus monkeys","volume":"20","author":"Lauritzen","year":"2022","journal-title":"J Thromb Haemost"},{"key":"2026102711113996600_bib13","unstructured":"European Medicines Agency\n          . HEMLIBRA Summary of Product Characteristics. Accessed 24 July 2026. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hemlibra-epar-product-information_en.pdf."},{"issue":"16","key":"2026102711113996600_bib14","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2026102711113996600_bib15","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1080\/13696998.2022.2115777","article-title":"Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe","volume":"25","author":"Mancuso","year":"2022","journal-title":"J Med Econ"},{"key":"2026102711113996600_bib16","first-page":"369","article-title":"Investigation into the acceptability of moderate-to-large volume subcutaneous injections in healthy volunteers: results from a single-center randomized controlled study","volume":"17","author":"Akinseye","year":"2024","journal-title":"Med Devices (Auckl)"},{"issue":"4","key":"2026102711113996600_bib17","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jtha.2023.12.016","article-title":"FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic","volume":"22","author":"Lentz","year":"2024","journal-title":"J Thromb Haemost"},{"key":"2026102711113996600_bib18","doi-asserted-by":"crossref","first-page":"107162","DOI":"10.1016\/j.ejps.2025.107162","article-title":"Model-informed drug development of Mim8 \u2013 a next-generation bispecific antibody for treatment of haemophilia A","volume":"212","author":"Kreilgaard","year":"2025","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"2026102711113996600_bib19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40272-020-00382-7","article-title":"Pharmacokinetics and clinical pharmacology of monoclonal antibodies in pediatric patients","volume":"22","author":"Temrikar","year":"2020","journal-title":"Paediatr Drugs"},{"issue":"3","key":"2026102711113996600_bib20","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/cpt.3150","article-title":"Subcutaneous administration of monoclonal antibodies: pharmacology, delivery, immunogenicity, and learnings from applications to clinical development","volume":"115","author":"Davis","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"2026102711113996600_bib21","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1177\/0091270009337512","article-title":"Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials","volume":"49","author":"Wang","year":"2009","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"2026102711113996600_bib22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/10600280231170650","article-title":"Fixed versus body-sized-based dosing of monoclonal antibodies","volume":"58","author":"Erstad","year":"2024","journal-title":"Ann Pharmacother"},{"issue":"7","key":"2026102711113996600_bib23","first-page":"e103207","article-title":"FRONTIER1 multiple ascending dose extension: a safety, tolerability, pharmacokinetics, and pharmacodynamics study of Mim8 in people with hemophilia A","volume":"9","author":"Chowdary","year":"2025","journal-title":"Blood Adv"},{"issue":"17","key":"2026102711113996600_bib24","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2517384","article-title":"Mim8 bispecific antibody prophylaxis in patients with hemophilia A with or without inhibitors","volume":"394","author":"Mancuso","year":"2026","journal-title":"N Engl J Med"},{"key":"2026102711113996600_bib25","unstructured":"World Medical Association\n          . WMA Declaration of Helsinki \u2013 Ethical Principles for Medical Research Involving Human Participant. https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki\/."},{"key":"2026102711113996600_bib26","unstructured":"ICH Harmonised Tripartite Guideline\n          . Guideline for Good Clinical Practice E6(R2), Current Step 4 Version. Accessed 24 July 2026. https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf."},{"issue":"4","key":"2026102711113996600_bib27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5482\/20170004","article-title":"Thromboembolic risks of non-factor replacement therapies in hemophilia","volume":"37","author":"Tiede","year":"2017","journal-title":"Hamostaseologie"},{"issue":"4","key":"2026102711113996600_bib28","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/ajh.27602","article-title":"2025 clinical trials update on hemophilia, VWD, and rare inherited bleeding disorders","volume":"100","author":"Jiang","year":"2025","journal-title":"Am J Hematol"},{"issue":"9","key":"2026102711113996600_bib29","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"2026102711113996600_bib30","unstructured":"Sarouei\n              K\n            , BarleraS, PolitoL, TobaruelaG, BiondoJML. Emicizumab prophylaxis in people with hemophilia A: summary of 10 years of safety data on thromboembolic events and thrombotic microangiopathy. Paper presented at: Thrombosis and Hemostasis Summit of North America (THSNA); 4-6 April 2024; Chicago, IL. Accessed 24 July 2026. https:\/\/medically.gene.com\/content\/dam\/pdmahub\/restricted\/haematology\/thsna-2024\/THSNA-2024-poster-sarouei-emicizumab-prophylaxis-in-people.pdf."},{"issue":"6","key":"2026102711113996600_bib31","doi-asserted-by":"crossref","first-page":"102180","DOI":"10.1016\/j.rpth.2023.102180","article-title":"Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults","volume":"7","author":"Konkle","year":"2023","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/20\/6946\/2595234\/blooda_adv-2025-019095-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/20\/6946\/2595234\/blooda_adv-2025-019095-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:11:53Z","timestamp":1793113913000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/20\/6946\/569761\/Denecimig-Mim8-prophylaxis-once-every-2-weeks-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":31,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026,10,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019095","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,27]]},"published":{"date-parts":[[2026,10,15]]}}}